GSK’s flop Potiga is picked up and headed for a quick makeover for pediatric epilepsy. Any bets on the prospective price?

GlaxoSmithKline took a considerable amount of heat last year when the pharma giant decided to yank a drug called Potiga, which had been sold for an extremely rare form of epilepsy caused by an errant KCNQ2 gene.